ZMB Member Ulf Dittmer
ZMB Member
Ulf Dittmer
Next ZMB-Member
Prof. Dr. Ulf Dittmer
Director of:
Institute of Virology
University Hospital Essen
Hufelandstr. 55
45147 Essen
- +49 201 723 3693
- Website
- Selected Publications
- Publication Metrics
-

- ZMB Research Program
Immunology, Infectious Diseases and Transplantation
Research Overview
- Persistent viral infections
- Innate immunity to retroviruses
- Basics of cellular and molecular immune defense mechanisms
- Immune regulation in retrovirus infections
- Immunotherapy for retroviral infections and virus-induced tumors
- Development of vaccines against retroviruses
- Antiviral activity of interferons
Selected Publications
-
HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistanceIn: Clinical Cancer Research, Vol. 29, 2023, Nr. 15, pp. 2894 – 2907
-
Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patientsIn: Nature Communications, Vol. 14, 2023, Nr. 1, 2835DOI (Open Access)
-
Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and PentamerIn: Immunity, Vol. 56, 2023, Nr. 11, pp. 2602 – 2620.e10
-
Metabolic requirements of NK cells during the acute response against retroviral infectionIn: Nature Communications, Vol. 12, 2021, Nr. 1, 5376DOI, Online Full Text (Open Access)
-
Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal FluidIn: Immunity, Vol. 54, 2021, Nr. 1, pp. 164DOI, Online Full Text (Open Access)
-
SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19In: Nature Communications, Vol. 12, 2021, Nr. 1, pp. 1813DOI (Open Access)
-
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide TherapyIn: Gastroenterology, Vol. 158, 2020, Nr. 8, pp. 2180 – 2194DOI (Open Access)
-
Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infectionIn: Journal of Hepatology, Vol. 70, 2019, Nr. 1 Suppl., pp. e81
-
MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearanceIn: Journal of Hepatology, Vol. 71, 2019, Nr. 4, pp. 685 – 698
-
CEACAM1 promotes CD8⁺ T cell responses and improves control of a chronic viral infectionIn: Nature Communications, Vol. 9, 2018, 2561DOI (Open Access)
-
Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growthIn: Nature Communications, Vol. 8, 2017, pp. 14600DOI (Open Access)
-
Circulating HIV-Specific Interleukin-21In: Immunity, Vol. 44, 2016, Nr. 1, pp. 167 – 178DOI (Open Access)
-
CEACAM1 induces B-cell survival and is essential for protective antiviral antibody productionIn: Nature Communications, Vol. 6, 2015, 6217DOI (Open Access)
-
BLT-humanized C57BL/6 Rag2⁻/⁻γc⁻/⁻CD47⁻/⁻ mice are resistant to GVHD and develop B- and T-cell immunity to HIV infectionIn: Blood, Vol. 122, 2013, Nr. 25, pp. 4013 – 4020DOI, Online Full Text (Open Access)
-
Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naïve T cells, and favors expansion of regulatory T cellsIn: Blood, Vol. 110, 2007, Nr. 12, pp. 3949 – 3958DOI (Open Access)
